For the latest in biomarkers & precision medicine, sign up for our monthly newsletter to be among the first to receive exclusive insights, in-depth market analyses, and expert articles directly to your inbox

Biomarkers for Clinical Development

Unveiling the Essential Criteria for Validating Clinical Biomarkers: A Comprehensive Guide

Biomarkers by Oxford Global will explore the essential criteria for validating clinical biomarkers, shedding light on the steps and challenges involved.
Biomarkers for Clinical Development

Advancing Biomarkers and Diagnostics in Diabetes Clinical Trials

Here, we speak to Matthias von Herrath about Biomarkers US 2023 and some current trends in the industry concerning research and technological development.
Biomarkers for Clinical Development

In Conversation With... Shuang Liang, Assistant Professor at UT Southwestern Medical Centre

Here, we speak to UT Southwestern’s Shuang Liang about monitoring TREM2 as a non-invasive diagnostic biomarker for NASH.
Biomarkers for Clinical Development

Non-Invasive Blood Tests for the Diagnosis of Liver Disease 

A recent FNIH study demonstrates the effectiveness of non-invasive blood tests in diagnosing non-alcoholic steatohepatitis (NASH), potentially reducing the need for invasive liver biopsies and improving NASH diagnosis.
Biomarkers for Clinical Development

N-of-1 Trials and Their Role in Improved Healthcare Outcomes

N-of-1 trials employ individualised treatments through double-blinded, randomised sequences to determine optimal approaches and enhance patient-doctor collaboration.
Biomarkers for Clinical Development

Challenges in Improving Patient Outcomes: Why Biomarkers Are Difficult to Commercialise

While biomarkers are integral to the identification and validation of disease treatment methods, there is a disconnect between existing validation approaches and their applications in commercialisation.
Biomarkers for Clinical Development

Tumour Heterogeneity and Immune Escape: Circumventing Some of the Biggest Roadblocks in Cancer Treatment

While the complexities associated with identifying tumour state and coordinating an effective immunotherapeutic response are many, pioneering healthcare providers are rising to the challenge.
Biomarkers for Clinical Development

Biomarkers in Psychiatry for Mental Health and Wellbeing

Biomarkers in psychiatry may have the potential to overcome the challenges associated with complications such as depression, bipolar disorder, and generalised anxiety.
Biomarkers for Clinical Development

Improving Approaches for Patient Selection Using Immuno-Oncology Biomarkers

ICIs – immune checkpoint inhibitors – have changed the landscape of therapeutic treatment for cancer and improved survival rates for patients with advanced malignancies. However, the wide variability in clinical response is a significant limitation to treatment.
Biomarkers for Clinical Development

Neurodegenerative Biomarkers and Treatment Strategies for Neurodegenerative Diseases

An understanding of the complex pathologies involved in patients with neurodegenerative diseases is integral to the identification of biomarkers and potential treatment methods for individuals who suffer from Alzheimer’s, Parkinson’s, and ALS. Here, we look at the development of dedicated biomarker strategies for helping to combat neurodegeneration.
Biomarkers for Clinical Development

Accelerating Drug Approval with Simoa®: Ultrasensitive Measurement of Biomarkers

Milena Dumont Milutinovic, Senior Manager of Field Applications at Quanterix, walks through the company's ultrasensitive biomarker assay technology.
Biomarkers for Clinical Development

Multimodal Biomarkers: How Screening Approaches Can Benefit From AI

We explore some of the different applications of AI in biomarkers for cancer analysis, including in urology and the characterisation of prostate cancer.

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things biomarkers